262 related articles for article (PubMed ID: 18237741)
1. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.
Lynch SM; Zhou C; Messer A
J Mol Biol; 2008 Mar; 377(1):136-47. PubMed ID: 18237741
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
Butler DC; Joshi SN; Genst E; Baghel AS; Dobson CM; Messer A
PLoS One; 2016; 11(11):e0165964. PubMed ID: 27824888
[TBL] [Abstract][Full Text] [Related]
3. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
Kvam E; Nannenga BL; Wang MS; Jia Z; Sierks MR; Messer A
PLoS One; 2009 May; 4(5):e5727. PubMed ID: 19492089
[TBL] [Abstract][Full Text] [Related]
4. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
[TBL] [Abstract][Full Text] [Related]
5. Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein.
Mahajan SP; Meksiriporn B; Waraho-Zhmayev D; Weyant KB; Kocer I; Butler DC; Messer A; Escobedo FA; DeLisa MP
Sci Rep; 2018 Dec; 8(1):17611. PubMed ID: 30514850
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
[TBL] [Abstract][Full Text] [Related]
7. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
Heng BC; Cao T
Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
[TBL] [Abstract][Full Text] [Related]
8. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.
Colby DW; Garg P; Holden T; Chao G; Webster JM; Messer A; Ingram VM; Wittrup KD
J Mol Biol; 2004 Sep; 342(3):901-12. PubMed ID: 15342245
[TBL] [Abstract][Full Text] [Related]
9. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.
Yuan B; Sierks MR
Neurosci Lett; 2009 Jul; 459(1):16-8. PubMed ID: 19394405
[TBL] [Abstract][Full Text] [Related]
10. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.
Zhou C; Emadi S; Sierks MR; Messer A
Mol Ther; 2004 Dec; 10(6):1023-31. PubMed ID: 15564134
[TBL] [Abstract][Full Text] [Related]
11. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
12. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
Joshi SN; Butler DC; Messer A
MAbs; 2012; 4(6):686-93. PubMed ID: 22929188
[TBL] [Abstract][Full Text] [Related]
13. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
14. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.
Chen YH; Wu KJ; Hsieh W; Harvey BK; Hoffer BJ; Wang Y; Yu SJ
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34205689
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies.
Gupta V; Sudhakaran IP; Islam Z; Vaikath NN; Hmila I; Lukacsovich T; Kolatkar PR; El-Agnaf OMA
PLoS One; 2020; 15(11):e0241773. PubMed ID: 33156828
[TBL] [Abstract][Full Text] [Related]
16. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
17. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
[TBL] [Abstract][Full Text] [Related]
18. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
Chaari A; Eliezer D; Ladjimi M
Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
[TBL] [Abstract][Full Text] [Related]
19. Identification of human alpha-synuclein specific single chain antibodies.
Maguire-Zeiss KA; Wang CI; Yehling E; Sullivan MA; Short DW; Su X; Gouzer G; Henricksen LA; Wuertzer CA; Federoff HJ
Biochem Biophys Res Commun; 2006 Nov; 349(4):1198-205. PubMed ID: 16973126
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.
Tsigelny IF; Bar-On P; Sharikov Y; Crews L; Hashimoto M; Miller MA; Keller SH; Platoshyn O; Yuan JX; Masliah E
FEBS J; 2007 Apr; 274(7):1862-77. PubMed ID: 17381514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
